NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Executive Summary
New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.
You may also be interested in...
Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?
NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.
Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?
NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.
1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva
Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.